Healthcare News 4

• "Word of Mouth" still rules
• 18F-FDG PET/CT: A Tremendous Molecular Imaging Tool
• 3 Ways for Drug Wholesalers to Grow
• 60% of diabetics reached their LDL cholesterol goal <70 on vytorin 10/20 vs. 21.5% in patients taking 10 mg o
• A briefcase-sized anti-counterfeiting detection device is nearly a joke, maybe it can detect and distinguish something counterfeit but it is extremely
• A Cure for Type I Diabetes
• A few sneaky ways virus can attacks us...
• A new era for drug wholesalers
• A new formulation
• A new window to health
• A patient friendly dosing
• A Tale of Two Recalls
• A Use for Genasense After All of These Years!!??
• A useful addition
• Abbot can bring muscle power to Enanta's brain power.
• About time
• Accomplia U.S. Approval Still Uncertain
• Advicor-the forgotten combination
• Agreement will speed development of SGN-40
• All Monoclonals not created equal
• Alternates to filling teeth
• AMO Acted Responsibly.
• AMO's Acquisition of Intralase: A clinician's perspective
• Amoxicillin once a day, beats 3 doses a day -- usually
• AMP, not sorbitol, appears to be the issue with Systane Free
• An improvement in acne treatment
• An interesting approach
• An interesting purchase by Thermo!
• Anesthesia in childhood: A needed "evil"
• Another avenue to explore against HIV
• Another first generation DES enters the market
• Another inotropic “Failure in Failure?”
• ANOTHER ocular allergy drop? What is ISTA thinking?
• Another Reason Adoption of Presbyopia Correcting IOLs is Slower than Expected
• Another Rituxan?
• Another Use for Revlimid?
• Antibiotics Use Leads to Resistance - DUH
• Anti-Depressant Drugs may have suicide as a side affect.
• Antioxidants - Why don't they work?
• Applications
• Aranesp associated with higher mortality rate when used in active cancer patients for anemia treatment
• Are NSAIDS on the way out ?
• Are we compromising the immune system?
• Aromatase Inhibitors (AI's) in Early Stage Breast Ca- The Standard?
• Artisan Phakic Intraocular Lens: limited market Appeal (No Threat to LASIK)
• As good as other atypical antipsychotics--only less so
• Asacol improves QOL
• Astelin
• Atrial Fibrillation Ablation - Is High Frequency Ultrasound the Answer?
• Autism is Rising: Treatments are Lagging
• Avandia and Osteoporosis
• AVASTIN WILL NOT GO AWAY (Wet Macular Degeneration Therapy)
• Avastin-New???
• Aventis' Ketek
• B@@BS -- Silicone Breast Implants: Congress to Debate with moot conclusions.
• Bad News for Genentech in Lung Cancer
• Bavituximab -Not As Targeted an Antibody as Its Peers
• Bepotastine has novel mechanism of action but clinical results are still pending
• Better Safe than Sorry- LASIK requires careful pre operative examinations
• BIGGEST NEWS OF 2007: AMO to Purchase Intralase
• Birth Control pills are dangerous and should be used rarely and safely.
• Blocking CCR9 in IBD
• Boomeritis and the hip
• Bulking up on generics
• Bush budget proposes AMP +150% instead of +250%
• C.E.R.A. Trial Stopped Upon DSMB Recommendation
• Ca + vitamin D for healthy bones
• Can compliance influence result?
• Cardinal Health settlement: Much more than a small fine
• Cause for Concern
• Cautious optimism for an important hepatitis C treatment
• Caveat Emptor-Point of Care Testing
• Celebrex in JRA, part deux
• Celebrex is effective for JRA with favorable short term safety profile
• Centocor's psoriasis drug
• Ceragenix Epiceram product has good potential to be effective in eczema and other skin conditions
• Cervical Cancer Vaccines: Brilliant Marketing by GSK beats Merck Again?
• CERVICAL CANCER: CAN WE HELP 70% OF YOUNG GIRLS
• Cessation still the gold standard
• CETP INHIBITORS- A PROBABLE CLASS ACTION EFFECT TO BE PROATHEROGENIC
• CHANGE holds promise for patients with this rare disease
• CHANGE is good
• Clearly NOT the panacea
• Cloning organs and body parts is not just a dream but a very possible reality
• CNTO 1275 will have an impact on the psoriasis market
• Combination or Sequential Therapy with Lapatinib?
• competitive value
• Confusing and problematic, but may have some truth to it
• Consumers are demanding increased choices and options with their medical and dental care.
• Continued use of amoxicillin
• Cooper Continues to Have Prolems With the Launch of Its Silicone Hydrogel Lenses
• Copying biologics: The devil is in the details
• Cord Blood stem cells hold great promise
• Corporate America and Health Care Reform, the Payers Take on the Dysfunction
• Corporate America Can Help Fix Health Care if it changes its Approach
• Corporate America CANNOT fix healthcare
• Cost-based Rx pricing will drive dramatic change in PBM and specialty pharmacy business models
• Could this Provide the Tipping Point for the Adoption of Health IT?
• CyberKnife by Accuray can serve clinical needs of many cancer patients
• Cyberknife, robotic-guided spinal radiosurgery proven effective for tumor control
• Dabigatran Etexilate for VTE prevention
• Deja Vu
• Demonstrating the Value of Your Hospital's Cardiac Care
• Dental Implant Capable of Dosing Drugs!
• DES in women
• Dilution of the Wellbutrin market by generic competition
• Disappointing but I think we'll get there yet....
• Does C.E.R.A. increase mortality in lung cancer patients?? Need to await final data analysis
• Don't Look to Health Plans for MLR Management
• Don't throw out the HDL baby with the Torcetrapib bathwater
• Doxil adds to Velcade's efficacy in relapsed/refractory multiple myeloma
• Doxorubicin Modifications Not the Answer in Hepatocellular Carcinoma
• Drug costs are the only remaining aspect of healthcare where costs can be squeezed
• Drug Eluting Stents:The Next Vioxx
• Drugs are but a tool, healthcare is priceless
• Drugs Effects on HDL Cholesterol Levels and Regression of Coronary Atherosclerosis
• Dual inhibitors are the next step in HNSCC molecular targeting?
• Dynogen's IBS study
• early menopause treated judiciously with hormones
• Ease of use will be the key
• Easier said than done
• EHR: Competition will drive costs lower and makes it more user friendly
• Electronic Health Records: Great idea, difficult to implement
• Empiric use of antibiotics against MRSA
• EMR (Electronic medical record), e-Rx, and Automated Record keeping
• End of a drug, but what about the target?
• Epinastine nasal spray starting phase 2 trial for allergic rhinitis in order to compete with Astelin
• Epinastine, an Inspired drug?
• ESA's use in cancer patients: Stick to indications and package insert!!!
• Evaluation of Change therapy
• Eventually generic formulation will take market share
• Evidence based medicine on "gum disease, pancreatic cancer may be linked"
• Exemestane Extended Therapy Improves Survival: No Surprises Here
• Exemestane, another drug to follow tamoxifen.
• Exforge approval – a “new” combination of old!
• Exilexis MEK inhibitor has promising preclinical activity, but will it translate to Clinical benefit??
• Expect changes in influenza immunization next year
• Experiment will harness expert information about Bird Flu and accelerate development of a Vaccine
• Extraordinary, Underappreciated and Full of Potential
• Exubera, review of new inhaled insulin
• Eye drops and preservatives
• False impression
• FDA drug approvals
• FDA Panel backs young adult antidepressant warning
• Federal Medicaid Pharmacy Drug Payment Cuts, Winners and Losers
• Finally - a head to head study.
• Forcing Physicians' Hand (Away from Writing Prescriptions)
• Formoterol and tiotropium give additive benefits in COPD
• FRACTIONALIZATION IN AESTHETIC SURGERY
• Free Drugs a Forward Thinking Approach to Drug Cost, Adherence and Chronic Disease
• Free Psych Meds Increase Productivity, Reduce Recidivism
• Functional improvement
• Gardasil unlikely to gain approval for men
• Gastrointestinal effects for Rituxan are rare and will have no impact on its use.
• Genasense makes sense in CLL
• Genasense yields higher response rates and longer remissions and survival in patients with refractory /relapsed CLL
• Gene therapy for RA
• Genentech has a huge problem with their credibility
• General Anesthetics: Poorly Understood
• generic biotech drugs
• Generic interest definitely on the rise
• Generic Wellbutrin
• Generic Zocor comes to Pharmacy Discount Programs
• Genes are only part of the story
• Gleevec after 5 Years
• Gleevec is drug of choice for frontline treatment of CML in chronic phase
• Glial Cells: The Nervous System is more than Neurons
• Glufosfamide is not effective in pancreatic cancer
• Goliath slays david
• Good move for both companies. Next move?
• Governmental intervention will make vaccines cheaper and more readily available
• Growth in the use of Generic Drugs and Its Impact on Medicare and Pharma
• GSK's Fluticasone Furoate
• Handwriting is only the symptom
• Health Care IT, Electronic Health Records (EHRs) and their Impact
• Health Care IT: the medium is the message
• Health Care Value Exchanges Coming to a Community Near You
• Health care value or quality?
• Health Information Technology Finally Gets Some Standards
• Health middlemen can be good for consumers
• Health Middlemen should be servants not masters!
• Health Middlemen! savior or curse?
• Health Plans, Medical Management and Medical Loss Ratios
• Healthways Year End Medicare Support Numbers and Future Guidance Show Continued Losses
• Helps Eczema, does little for Psoriasis
• Her2/New Vaccine: Too New To Draw Conclusions
• Here's a Definite Financial Benefit for Investing in Health IT
• Hip resurfacing is small potatoes
• Hormone Therapy and Macular Degeneration: Results from the Women’s Health Initiative
• How low CAN you go?
• How will AIs be used
• How will it compare?
• HPV vaccine- Gardasil (Merek) - Who will cover the cost?
• HPV vaccine is effective, safe, and should be included in routine immunization schedule
• HPV vaccine is here to stay, for men too
• HPV Vaccine: A major advance for women's (and men's) healthcare worldwide
• HRT more risky than diabetes
• HUGE INDUSTRY CHANGES WOULD RESULT FROM Merck KGaA completing a Divestiture of it's Generic Business unit
• HuMax-CD20 Will Challenge Rituxan Market
• HUMIRA FOR CROHN'S DISEASE
• Humira in Crohn's disease
• I would expect only mild interest
• If doctors prescribe stimulants, patients are going to abuse them
• If If If IVREA Can Develop a Product for Onchomychosis
• IL-7 Immunotherapy for HIV, Pre-clinical data looks promising
• I'm not sleepy any more, but I'm FAT!
• Impact of PDMA Injunction
• Implantable hemodynamic monitoring for heart failure patients: Not ready for prime time
• Implications of new breast cancer prognostic methodology
• Importation law will create change in wholesale and retail industries
• Increased Education = Decreased Misuse
• Increased risk of fractures with Avandia (rosiglitazone)
• Increasing depth
• Increasing Threat
• Industry sponsored trials equal biased results?
• Infectobesity: Do not quit your diet or cancel your gym membership anytime soon
• INHALED INSULIN IS LIKELY HERE TO STAY
• Inhaled Insulin is not the answer
• Insomnia is usually a symptom not a disease
• Interesting Info
• International Experience Precedes That of the U.S.
• Intralase enabled keratoplasty
• Intravitreal Triamcinolone Effective in Diabetic Macular Swelling
• Is "on label" use of DES the solution ?
• Is Allovectin better than Genasense for metastatic melanoma: The Jury is still out
• Is once a day amoxicillin worth the price?
• Is PolyHeme doomed ?
• Is PROMUS promising ?
• Is Rituxan less safe than thought?
• Is Rituxan Too Toxic?
• Is the survival benefit for Nexavar clinically meaningful in hepatocellular carcinoma??
• Is this the future of laboratory automation
• ISTA takes the lead in topical NSAID therapy
• It is not important in America anymore
• IT only part of the answer
• Its about time Alkermes is looking at the greatest potential benefit of this naltrexone formulation
• Its not your Standard Commercial Disease Management Program
• It's Right Before Your Eyes
• JCAHO Patient Safety Goal to Reduce Medication Errors
• Ketek is on the way out
• Killed a great drug
• Knee jerk response
• Known and now "finally" proven
• Lack of Knowlegge of Drug Pharmacology Is A Recipe for Disaster
• Lapatinib Has Large Potential Market
• Lapatinib is effective in combination with Xeloda in relapsed/refractory metastatic Breast Cancer
• Laser Vision Correction will continue to be popular.
• Lenalidomide is effective and safe oral agent for CLL
• Less Money, Less Access
• Less Relevant for Type II than Type I
• Levosimendan – another inotropic drug about to disappoint in “failure”?
• LIBIDO BOOSTER FOR WOMEN
• Like using a battering ram to crack a walnut
• Limited victory for SNN
• Little effect likely of OTC fat blocker
• Long in coming
• Look for Overall Growth in Self-Pay Market
• Loss for Pfizer and patients
• Low HDL
• Lower is Better!
• LYMPHOSTAT-B PHASE 3 TRIALS IN LUPUS (GLAXO SMITHKLINE, HGS)
• Macrolides lead to antibiotic resistance, but do not expect a drastic change in doctor's antibiotic prescriptions pattern.
• Making a good drug better?
• Making patients feel better
• Managing litigation and settlements in connection with botched surgery.
• Marketing and labeling will determine proper use
• Matria's New and Expanded Disease Management Accounts
• Medical Loss Ratios as Lazy Metric
• Medicare Part D - Confusion Renewed
• Medicare Part D and Medicare Advantage Providers, Pharmaceutical Costs and Profitability
• MedImmune's FluMist approved for refrigerator storage for 07-08 season
• MedPointe/Astelins rapid response
• Mental Health Parity Will Occur
• Merck has shot itself in the foot!
• Merck's mistake?
• Merck's UK Clinical Gardasil Trial halted early
• Methadone is a two-edged sword
• Microvolt T-Wave Alternans - Not cost effective in private cardiologists office
• Minimally invasive atrial fibrillation ablation
• Missing Lessons in Torcetrapib Paradox
• Molecular Diagnostics in Breast CA- Now FDA approved!
• Molecularly-targeted drugs make the difference?
• Money in diagnostics??
• Money talks, nobody walks
• Monoclonal Antibody Failure in Advanced Prostatic cancer
• More confusion
• More good news for Concerta are bad for Ritalin
• More pacemakers used in heart failure?
• More restricted use for Erythropietins will be the rule in chronic renal failure
• More risks associated with stimulant use in ADHD
• More Rituxan problems
• MRSA Pneumonia - What to do?
• MRSA pneumonia- A different beast
• MRSA pneumonia- New Alternatives to Vancomycin are needed
• Myeloma Redux
• New Algorithm in Hormonal Therapy of Breast Cancer? Where have they been?
• New Bill will enhance competition and lead to cheaper biologicals
• New device from Medtronic to compete with X-STOP interspinous spacer
• New drug for what ails Americans
• New long-acting GLP-1 receptor agonist fom Pfizer/Biorexis?
• New Study confirms Gleevec's supremacy as frontline therapy for chronic phase CML
• News not new, consistent with development intent.
• Nexavar and Hepatocellular carcinoma HCC
• Nexavar---- king of the rare tumors
• Nexavar, Vitamin N?
• Nexavar: Are the responses in advanced hepatocellullar carcinoma significant and durable??
• Niacin -a renual of use to raise HDL
• Niacin plus a statin can reduce myocardial infarctions and strokes in heart patients by 70%
• Niacin...it's deja vu all over again.
• No Brainer
• No surprise!
• Non genetic factors determining warfarin dose
• Northfield Plans to File BLA for Blood Substitute This Year
• Not surprised
• Not surprised with asthma but details of study lacking..
• Not surprising
• Nothing new
• Nothing new
• Numax is effective, but at what price?
• Obagi Medical Products Clenziderm should have a positive impact
• Older antipsychotics just as good?
• OmpC for CD
• On label use is based on science - off label on speculation
• Once daily amoxicillin equivalent to penicillin given 4 times daily in curing tonsillitis/pharyngitis
• One of the many reasons for IT
• Only if used correctly
• Oral anticoagulant has similar efficacy and safety to Enoxaparin
• Oral Dabigatran etexilate is effective for prevention of VTE
• Oral Delivery of TNF Blockers
• Oral TNF blockers
• OTC lower dose Xenical...Primary doc has some hope
• Outsourcing drug development and clinical trials can expect rapid FDA drug clearance
• Outsourcing of Clinical Trials Very Problematic
• Outsourcing of Medications to Asia Good and Bad
• p4p and capitation
• P4P IS HERE
• Pay for performance is a reality - the guidelines will determine if it is a benefit for patients
• Pay for Performance Needs More Pay to Get More Performance
• PDMA delay will increase scrutiny of pharmacies and wholesalers
• Pentacel not the first 5-in-1 vaccine out there. GSK got there first!
• Percutaneous Aortic valve replacement
• Perhaps the start of something BIG
• Personalized medicine was in the works, soon it will be in your medicine cabinet.
• Pertuzumab may have a role in advanced ovarian cancer but watch for Cardiotoxicity
• Pfizer will rebound stronger than ever
• Pfizer’s loss – lessons for all of us
• Pfizer's Future
• Pharmaceutical firms influence their results.
• Physicians, Quality Reporting and Pay-for-Performance
• Placebo for asthma
• Playing third fiddle
• Poor supervision or unqualified professionals creating problems
• portable device will help to screen for counterfeit drugs
• Potential Comeback of Anti-schizophrenia Drug Iloperidone, Or Maybe Not!
• Potential impact of an improved Niacin
• Preventing Law Suits Before Laser Vision Correction is Done
• Preventive care saves lives and saves dollars
• Primary Doctor not surprized
• Prochymal for Crohn's disease
• procrit and epogen-when marketing or good medicine
• Provider Reimbursement by Health Plans and its Potential Longer Term Impact on Health Plan Profitability
• Putting the cart before the horse.
• Recalling your implant is not the same as the break pads in your car!
• Remember the "Rats Nest" is created by the Rats.
• Remember to do currently recommended screening
• Renal cancer: Are We Surprised?
• Restrictions on civilians for laser eye correction is unlikely/limited.
• Resurfacing expands market of joint replacement, slightly
• Resurfacing revisited
• Retail medical clinics-an inevitable development
• Re-treatment of NHL with I-131 tositumomab (Bexxar)
• Revlimid and valcade, NOT Thalidomide are the way of the future for Multiple myeloma
• Revlimid is effective for CLL, but the real promise is for combination therapy
• Rimonabant effective in treating and preventing diabetes
• Rimonabant keeps looking better for treatment of metabolic syndrome
• Rimonabant: First line in diabetes & metabolic syndrome
• Rituxan- A Bump in the Road?
• Rituxan associated With Progressive Multifocal Leukoencephalopathy
• RNA Interference (RNAi) Offers New Options in Medical Treatment
• Rotateq may be associated with intussusception
• Rotigotine transdermal patch effective for restless leg syndrome
• Scleral expansion: A legitimate contender in the presbyobia arena?
• Selective use of anti-TNFs
• Self Pay Markets - Consumer Nirvana, I think not
• Sexual arousal in women is complicated
• Size Matters
• Small Can Be Beautiful
• Smoking pot gives you the munchies? Rimonabant will make you svelt!
• Sorafinib a Bust in Melanoma?
• Sound Reasons Why It Should Stay Old
• Spacers DO matter with HFA inhalers
• Sprycel's role is limited to Imatinib resistant CML
• Statins for Heart Failure – More and Better
• Statistical Associations do not indicate causality
• Stop breathing and you won't cough
• Stopping cervical cancer
• Study Excludes Patients for Who Second Generation Antipsychotics are Targeted
• Success of Retail Clinics in Pediatrics Will Depend on perceived value
• Suicide warnings for antidepressants unlikely to decrease their usage
• Surgery for herniated lumbar disc
• Surprise!!!!
• Switching Retinoids during acne therapy does improve outcomes
• Systane Free Recall Does Not Impact Travatan Z
• Targeted cancer therapy with a moving Target
• Targeted Therapy- The Future of Oncology is a Bulls-eye Rather Than Slash & Burn
• Technology of the future
• Telcyta a bust?
• Telcyta fails to make the grade, but.....
• Telcyte and Telik: It's All Over
• TEVA seeks 180 days exclusivity for Rabeprazole Sodium-Delayed Release Tablets
• Texas is only the first
• The "safe" antidepressants have, but may now not be prescribed as freely as water
• The After Taste is Not Sweet
• The beginning of a shift in power for the healthcare system
• The CHANGE trial
• The Controversy Continues For Silicone Breast Implants
• The evidence-based use of erythropoetin in cancer patients
• The Future Is E-Detailing
• The future of clinical laboratory diagnostics
• The future of government funded HMOs and Disease Management
• The Health Care Middleman, Required or Optional
• The Importance of a Unified Electronic Health Record
• The need for a rational evaluation of "rationale drugs"
• The next LASIK procedure?
• The question remains: Is high affinity more effective or safer?
• The Side Effects of Humira
• The Sponge eventually will cost Allendale Pharmaceuticals, Inc more than it makes on the product.
• The Value of Monitering Intraocular Pressure
• Thermo Fisher Scientific Acquires Cohesive Technologies Inc: A hand in a velvet glove
• Think resistant
• This is your brain on drugs
• This makes sense-but will there be issues?
• Too little, too late?
• Topical anesthetics are dangerous if used incorrectly
• Torcetrapib: CV Outcome studies Matter
• Torisel and success
• Torisel Well On Way to FDA Approval for Renal Cell Carcimoma
• Torisel's Efficacy- Just the Tip of the Iceberg?
• Treatment of African trypanosomiasis
• TRIAD Hospitals Slowing Down
• TRIAD is still a company to watch for signs of things to come
• Triple therapy for allergic conjunctivitis
• Trouble Ahead for Independent Pharmacists
• U.S. Costs for Correction of Distance Vision Impairment
• UCB's Cimzia
• Ultrafiltration, a Promising Alternative for Acute Heart Failure.
• UNCERTAINTY IN PHASE II TRIALS
• Universal use of Zostavax is a fantasy
• Urban Legend??
• US Government Encouraging More Players onto Field in Vaccine Game
• US Healthcare is Uncompetitive
• US Wholesalers are Missing China Opportunity
• Use of Intacs Limited to Treatment of Corneal Ectasias
• Using Electronic Health Technologies Correctly to Improve Patient Safety
• Using Saliva to Diagnose Disease?
• Vaccine should be mandatory for boys as well as girls
• Value Driven Health Care Picks Up Speed
• Velcade use is expanded to Mantle Cell Lymphoma
• Very Bright Future. Wear Sunglasses.
• Vyvanse approvable and likely to be on market in next 3-5 months
• Vyvanse for ADHD: Expected to Reach Market in Second Quarter 2007
• Vyvnase Schedule II assignment will limit its use
• We all know of "healthy" young people who kill themselves--if only they had diabetes
• We also have increased our advertising budget
• We need to fix the system
• Welcome to Never-Neverland!
• Welllpoint - Another Health Plan, Another Increase in Medical Loss Ratio's (MLR)
• Wellness Will Become an Integral Part of Employer and Government Sponsored Health Care
• What is old is new again
• What is the future of tamoxifen?
• What is the relationship between statins, LDL, and Parkinson's disease
• What we can do to reduce medication errors
• What we do not know can hurt us
• What we do not understand hurts us
• What's Old is New Again
• When will they learn
• When will we stop underprescribing niacin for atheroprevention?
• Where East meets West
• Where is the old lace?
• Wholesalers could benefit from importation
• Will generics be the next battleground for wholesalers?
• Will it be better?
• Will it take off?
• Will melanoma results hurt Nexavar ?
• Will the OTC laser hair systems have an impact??
• Will this fly?
• With varenicline, nicotine patch will go up in smoke
• WSJ overstates its case against PBMs
• WYETH intends to close KEY manufacturing plant and former R&D center, BIG MISTAKE
• Xeloda = Versatility
• Xeloda Use Will Increase Based on Phase III XELOX data
• Xolair apprehension
• Xolair's anaphylaxis: Still helpful for severe asthma. Also give the patient an Epi Pen or Twinject
• Xolair's black mark
• Yaz's new indication unlikely to make much difference
• Yet Another Recall in the Ophthalmic Market: Systane Free
• Zileuton competes with inhaled steroids, not Singulair. It needs to pay for those Liver Function Tests for increased acceptance.
• ZymoGenetics Files for U.S. Thrombin Approval; Company Eyes Million-Surgery Market
• Zyprexa and diabetes
• Zyprexa's sales numbers likely to stay level